170 related articles for article (PubMed ID: 18206598)
1. Effectiveness of eprosartan in diabetic hypertensive patients.
Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
Eur J Intern Med; 2008 Jan; 19(1):27-31. PubMed ID: 18206598
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
[TBL] [Abstract][Full Text] [Related]
3. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
de la Sierra A; Muñoz A; Arcos E; López JS; Relats J;
Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
[TBL] [Abstract][Full Text] [Related]
4. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I; Chilvers M; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[TBL] [Abstract][Full Text] [Related]
5. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS; McKay DW; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[TBL] [Abstract][Full Text] [Related]
6. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
7. [Anti-hypertensive effect of eprosartan in diabetic patients].
Robles NR; Velasco J; Jiménez Pérez JL; Alonso FJ; Blanco J; Masot J; Matilla C; Nieto J; Romero F; Gamero MJ
An Med Interna; 2004 May; 21(5):223-6. PubMed ID: 15176923
[TBL] [Abstract][Full Text] [Related]
8. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
Dhakam Z; McEniery CM; Yasmin ; Cockcroft JR; Brown MJ; Wilkinson IB
Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
[TBL] [Abstract][Full Text] [Related]
9. [Stress-associated hypertension in the work place: results of the STARLET project].
Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
[TBL] [Abstract][Full Text] [Related]
10. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
Hanon O; Berrou JP; Negre-Pages L; Goch JH; Nádházi Z; Petrella R; Sedefdjian A; Sévenier F; Shlyakhto EV; Pathak A
J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
[TBL] [Abstract][Full Text] [Related]
11. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
Labiós M; Martínez M; Gabriel F; Guiral V; Munoz A; Aznar J
Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
Pathak A; Hanon O; Negre-Pages L; Sevenier F;
Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
[TBL] [Abstract][Full Text] [Related]
13. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Fogari R; Derosa G; Zoppi A; Rinaldi A; Preti P; Lazzari P; Mugellini A
Hypertens Res; 2008 Jan; 31(1):43-50. PubMed ID: 18360017
[TBL] [Abstract][Full Text] [Related]
14. Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment.
Labiós M; Martínez M; Gabriel F; Guiral V; Dasi F; Beltrán B; Muñoz A
J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):24-30. PubMed ID: 19286755
[TBL] [Abstract][Full Text] [Related]
15. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
[TBL] [Abstract][Full Text] [Related]
16. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
[TBL] [Abstract][Full Text] [Related]
17. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
Fogari R; Zoppi A; Ferrari I; Mugellini A; Preti P; Lazzari P; Derosa G
Horm Metab Res; 2009 Dec; 41(12):893-8. PubMed ID: 19708000
[TBL] [Abstract][Full Text] [Related]
19. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV; Rudmann MA
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of lercanidipine in the general practice setting].
Robles NR; Canelada JA; Iglesias M; Angulo E; López Acedo A; Díaz Olea E; Cidoncha F; Guerras M; Fuentes J; Garrido J; Lapie J; Peña J; Aguilar A; Hidalgo P
An Med Interna; 2003 Jun; 20(6):282-6. PubMed ID: 12848597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]